GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Frazier Lifesciences Acquisition Corp (NAS:FLAC) » Definitions » Earnings Yield (Joel Greenblatt) %

Frazier Lifesciences Acquisition (Frazier Lifesciences Acquisition) Earnings Yield (Joel Greenblatt) % : -2.88% (As of Sep. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Frazier Lifesciences Acquisition Earnings Yield (Joel Greenblatt) %?

Frazier Lifesciences Acquisition's Enterprise Value for the quarter that ended in Sep. 2022 was $176.60 Mil. Frazier Lifesciences Acquisition's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 was $-5.09 Mil. Frazier Lifesciences Acquisition's Earnings Yield (Joel Greenblatt) for the quarter that ended in Sep. 2022 was -2.88%.

The historical rank and industry rank for Frazier Lifesciences Acquisition's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

FLAC's Earnings Yield (Joel Greenblatt) % is not ranked *
in the Diversified Financial Services industry.
Industry Median: -1.64
* Ranked among companies with meaningful Earnings Yield (Joel Greenblatt) % only.

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Frazier Lifesciences Acquisition's Forward Rate of Return (Yacktman) % for the quarter that ended in Sep. 2022 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Frazier Lifesciences Acquisition Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Frazier Lifesciences Acquisition's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Frazier Lifesciences Acquisition Earnings Yield (Joel Greenblatt) % Chart

Frazier Lifesciences Acquisition Annual Data
Trend Dec20 Dec21
Earnings Yield (Joel Greenblatt) %
- -0.79

Frazier Lifesciences Acquisition Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Earnings Yield (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only -0.60 -0.79 -0.85 -1.81 -2.88

Competitive Comparison of Frazier Lifesciences Acquisition's Earnings Yield (Joel Greenblatt) %

For the Shell Companies subindustry, Frazier Lifesciences Acquisition's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Frazier Lifesciences Acquisition's Earnings Yield (Joel Greenblatt) % Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Frazier Lifesciences Acquisition's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Frazier Lifesciences Acquisition's Earnings Yield (Joel Greenblatt) % falls into.



Frazier Lifesciences Acquisition Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Frazier Lifesciences Acquisitions Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2021 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=-1.366/171.84525
=-0.79 %

Frazier Lifesciences Acquisition's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.09 Mil.



Frazier Lifesciences Acquisition  (NAS:FLAC) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


Frazier Lifesciences Acquisition Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Frazier Lifesciences Acquisition's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Frazier Lifesciences Acquisition (Frazier Lifesciences Acquisition) Business Description

Traded in Other Exchanges
N/A
Address
601 Union Street, Two Union Square, Suite 3200, Seattle, WA, USA, 9810
Frazier Lifesciences Acquisition Corp is a blank check company.
Executives
David Joseph Topper director, officer: Chief Financial Officer C/O GENERAL ATLANTIC SERVICE COMPANY, LP, 55 EAST 52ND STREET, 32ND FLOOR, NEW YORK NY 10055
Krishna R Polu director C/O RAPTOR PHARMACEUTICAL CORP, 7 HAMILTON LANDING, SUITE 100, NOVATO CA 94949
Robert Jr. Baltera director 6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Carol Giltner Gallagher director C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Michael Bigham director 890 WINTER STREET, WALTHAM MA 02451
Deerfield Management Company, L.p. (series C) 10 percent owner, other: Possible Member of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Deerfield Mgmt L.p. 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Partners, L.p. 10 percent owner, other: Possible Member of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
James E Flynn 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Ole Andreas Halvorsen 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Parent Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Rose Sharon Shabet 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Illiquid Investments Sub-master Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Gp Llc 10 percent owner 55 RAILROAD AVENUE, GREENWICH CT 06830